This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

TNX-100

Roche Holding AG

Drug Names(s): TNX-100, 5D12

Description: Antibodies targeting CD40 on the surface of B cells have the potential to block B cell responses, and thus dampen autoimmune responses.

TNX-100 is similar to IDEC-131, also an anti-CD40 ligand antibody.

Deal Structure: Revenue splits for this drug are BioMedTracker estimates.

Tanox licensed this antibody from a Dutch subsidiary of Chiron.

In August 2007, Genentech completed the acquisition of Tanox.

In March 2009, Roche and Genentech announced that they signed a merger agreement under which Roche will acquire the outstanding publicly held interest in Genentech for US95.00 per share in cash, or a total payment of approximately US$46.8 billion to equity holders of Genentech other than Roche. The acquisition was completed on March 26, 2009.

Partners: Novartis AG


TNX-100 News

Pink Sheet ICAAC In Brief


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug